COMPASS Pathways (CMPS)
NASDAQ: CMPS
· Real-Time Price · USD
4.09
0.11 (2.76%)
At close: May 01, 2025, 3:33 PM
2.76% (1D)
| Bid | 4.09 |
| Market Cap | 280.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -155.12M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -1.78 |
| Forward PE | -2.74 |
| Analyst | Buy |
| Ask | 4.1 |
| Volume | 578,545 |
| Avg. Volume (20D) | 1,107,780 |
| Open | 3.98 |
| Previous Close | 3.98 |
| Day's Range | 3.88 - 4.15 |
| 52-Week Range | 2.49 - 9.63 |
| Beta | 2.35 |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu...
Industry Medical - Care Facilities
Sector Healthcare
IPO Date Sep 18, 2020
Employees 166
Stock Exchange NASDAQ
Ticker Symbol CMPS
Website https://compasspathways.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 229.67% from the latest price.
Stock Forecasts2 months ago
+5.95%
Compass Pathways shares are trading higher. The co...
Unlock content with
Pro Subscription
6 months ago
-23.1%
Compass Pathways shares are trading lower after the company announced it pushed its topline data readout from its COMP005 Phase 3 trial to Q2 2025 and its COMP006 data will be announced after the 26-week time point.
